ReviewNature medicine1995
Complement-specific antibodies: designing novel anti-inflammatories.
Review in Nature medicine, 1995. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Shifting From Systemic to Precision-Targeted Complement Therapies: Opportunities and Hurdles.European journal of immunology · 2026Review
- Shiga Toxin-Producing E. coli and Hemolytic Uremic Syndrome: A Study of the 2022 Outbreak in Turkey.Medical science monitor : international medical journal of experimental and clinical research · 2024Article
- Application of eculizumab, a terminal complement inhibitor, in the management of atypical hemolytic uremic syndrome in a 14-month-old Chinese pediatric patient: a case report.Frontiers in pediatrics · 2024Article
- Anti-complement 5 antibody ameliorates antibody-mediated rejection after liver transplantation in rats.Frontiers in immunology · 2023Article
- Exploiting protease activation for therapy.Drug discovery today · 2022Review
- Emerging Role of C5 Complement Pathway in Peripheral Neuropathies: Current Treatments and Future Perspectives.Biomedicines · 2021Review
- Eculizumab as an emergency treatment for adult patients with severe COVID-19 in the intensive care unit: A proof-of-concept study.EClinicalMedicine · 2020Article
- Complement-targeted therapy: development of C5- and C5a-targeted inhibition.Inflammation and regeneration · 2016Review
- Complement in paroxysmal nocturnal hemoglobinuria: exploiting our current knowledge to improve the treatment landscape.Expert review of hematology · 2014Review
- The discovery of medicines for rare diseases.Future medicinal chemistry · 2014Article
- Anti-Complement Treatment in Paroxysmal Nocturnal Hemoglobinuria: Where we Stand and Where we are Going.Translational medicine @ UniSa · 2014Article
- Aurin tricarboxylic acid protects against red blood cell hemolysis in patients with paroxysmal nocturnal hemoglobinemia.PloS one · 2014Article
- Humoral-targeted immunotherapies in multiple sclerosis.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2013Review
- Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization.Haematologica · 2010Article
- Paroxysmal nocturnal hemoglobinuria: pathophysiology, natural history and treatment options in the era of biological agents.Biologics : targets & therapy · 2008Article
- Article
- Formation of complement membrane attack complex in mammalian cerebral cortex evokes seizures and neurodegeneration.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2003Article
- New therapies in development for autoimmune diseases: their rationale for combination treatment.Springer seminars in immunopathology · 2001Review
- Inhibition of complement as a therapeutic approach in inflammatory central nervous system (CNS) disease.Molecular medicine (Cambridge, Mass.) · 1999Review
- Targeting of functional antibody-CD59 fusion proteins to a cell surface.The Journal of clinical investigation · 1999Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.